Potentiation of antidepressant-like activity with lithium: Mechanism involved

Current Drug Targets

Volumn 7, Issue 2, 2006, Pages 159-163

  Chenu, Franck ^a   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT1B receptor; Antidepressant; FST; Lithium; Mechanism of action; Serotonin

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CORTICOTROPIN; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRINDOLE; LITHIUM CHLORIDE; LITHIUM SALT; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; OSEMOZOTAN; PAROXETINE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; LITHIUM;

BRAIN CORTEX; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FORCED SWIMMING TEST; HIPPOCAMPUS; HUMAN; LONG TERM CARE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SHORT COURSE THERAPY; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; BIPOLAR DISORDER; BRAIN; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; RECEPTOR, SEROTONIN, 5-HT1B;

EID: 33644858602     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945006775515392     Document Type: Review

References (95)

1. Sheard, M.H. and Aghajanian, G.K. (1970) Life Sci., 9, 285-90.
2. Perez-Cruet, J., Tagliamonte, A., Tagliamonte, P. and Gessa, G.L. (1971) J. Pharmacol. Exp. Ther., 178, 325-30.
3. Grahame-Smith, D.G. and Green, A.R. (1974) Br. J. Pharmacol., 52, 19-26.
4. Berggren, U. (1985) J. Neurol Transm., 61, 175-81.
5. Eroglu, L. and Hizal, A. (1987) Pol. J. Pharmacol. Pharm., 39, 667-73.
6. Ghoshdastidar, D. and Poddar, M.K. (1990) Indian J. Exp. Biol., 28, 444-50.
7. Goodwin, G.M., De Souza, R.J., Wood, A.J. and Green, A.R. (1986) Psychopharmacology (Berl)., 90, 488-93.
8. Mekler, G. and Woggon, B. (1997) Pharmacopsychiatry, 30, 272-3.
9. Baptista, T.J., Hernandez, L., Burguera, J.L., Burguera, M. and Hoebel, B.G. (1990) J Neural. Transm. Gen. Sect., 82, 31-41.
10. Treiser, S.L., Cascio, C.S., O'Donohue, T.L., Thoa, N.B., Jacobowitz, D.M. and Kellar, K.J. (1981) Science, 213, 1529-31.
11. Blier, P. and De Montigny, C. (1985) Eur. J. Pharmacol., 113, 69-77.
12. Price, L.H., Charney, D.S., Delgado, P.L. and Heninger, G.R. (1990) Psychopharmacology (Berl), 100, 3-12.
13. Sangdee, C. and Franz, D.N. (1980) Biol. Psychiatry, 15, 59-75.
14. Sharp, T., Bramwell, S.R., Lambert, P. and Grahame-Smith, D.G. (1991) Neuropharmacology, 30, 977-84.
15. Goodwin, G.M. (1989) Prog. Neuropsychopharmacol. Biol. Psychiatry, 13, 445-51.
16. Nag, M. (2004) Indian J. Exp. Biol., 42, 941-4.
17. Moorman, J.M. and Leslie, R.A. (1998) Neuropharmacology, 37, 357-74.
18. Redrobe, J.P. and Bourin, M. (1999) Psychopharmacology (Berl.), 141, 370-7.
19. Massot, O., Rousselle, J.C., Fillion, M.P., Januel, D., Plantefol, M. and Fillion, G. (1999) Neuropsychopharmacology, 21, 530-41.
20. Odagaki, Y., Koyama, T., Matsubara, S., Matsubara, R. and Yamashita, I. (1990) J. Psychiatr. Res., 24, 271-7.
21. Januel, D., Massot, O., Poirier, M.F., Olie, J.P. and Fillion, G. (2002) Psychiatry Res., 111, 117-24.
22. Muraki, I. (2001) Hokkaido Igaku zasshi, 76, 57-70.
23. Haddjeri, N., Szabo, S.T., de Montigny, C. and Blier, P. (2000) Neuropsychopharmacology, 22, 346-56.
24. Blier, P., de Montigny, C. and Tardif, D. (1987) Synapse, 1, 225-32.
25. Petit-Demouliere, B., Chenu, F. and Bourin, M. (2005) Psychopharmacology (Berl.), 177, 245-255.
26. Jacobsen, J.P. and Mork, A. (2004) Brain. Res., 1024, 183-92.
27. Muraki, I., Inoue, T., Hashimoto, S., Izumi, T., Ito, K., Ohmori, T. and Koyama, T. (1999) Eur. J. Pharmacol., 383, 223-9.
28. Cordeiro, M.L., Gundersen, C.B. and Umbach, J.A. (2002) Brain Res., 953, 189-94.
29. Pazos, A. and Palacios, J.M. (1985) Brain Res., 346, 205-30.
30. Verge, D., Daval, G., Marcinkiewicz, M., Patey, A., el Mestikawy, S., Gozlan, H. and Hamon, M. (1986) J. Neurosci., 6, 3474-82.
31. Bruinvels, A.T., Palacios, J.M. and Hoyer, D. (1993) Naunyn Schmiedebergs Arch. Pharmacol., 347, 569-82.
32. Wegener, G., Linnet, K., Rosenberg, R. and Mork, A. (2000) Brain Res., 871, 338-42.
33. Muraki, I., Inoue, T., Hashimoto, S., Izumi, T., Ito, K. and Koyama, T. (2001) J. Neurochem., 76, 490-7.
34. Malagie, I., Trillat, A.C., Bourin, M., Jacquot, C., Hen, R. and Gardier, A.M. (2001) J. Neurochem., 76, 865-71.
35. Malagie, I., David, D.J., Jolliet, P., Hen, R., Bourin, M. and Gardier, A.M. (2002) Eur. J. Pharmacol., 443, 99-104.
36. Carli, M. and Reader, T.A. (1997) Synapse, 27, 83-9.
37. Carli, M., Afkhami-Dastjerdian, S. and Reader, T.A. (1997) Neurochem. Res., 22, 427-35.
38. Basselin, M., Chang, L., Seemann, R., Bell, J.M. and Rapoport, S.I. (2005) Neuropsychopharmacology, 30, 461-72.
39. Wegener, G., Bandpey, Z., Heiberg, I.L., Mork, A. and Rosenberg, R. (2003) Psychopharmacology (Berl.), 166, 188-94.
40. Gambarana, C., Ghiglieri, O., Masi, F., Scheggi, S., Tagliamonte, A. and De Montis, M.G. (1999) Brain Res., 826, 200-9.
41. Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T. and Koyama, T. (2004) Eur. J. Pharmacol., 489, 187-91.
42. Carli, M., Morissette, M., Hebert, C., Di Paolo, T. and Reader, T.A. (1997) Biochem. Pharmacol., 54, 391-7.
43. O'Dell, L.E. and Parsons, L.H. (2004) J. Pharmacol. Exp. Ther., 311, 711-9.
44. Yan, Q.S. and Yan, S.E. (2001) Eur. J. Pharmacol., 418, 55-64.
45. Bentue-Ferrer, D., Reymann, J.M., Rousselle, J.C., Massot, O., Bourin, M., Allain, H. and Fillion, G. (1998) Eur. J. Pharmacol., 358, 129-37.
46. Galloway, M.P., Suchowski, C.S., Keegan, M.J. and Hjorth, S. (1993) Synapse, 15, 90-2.
47. Gottberg, E., Grondin, L. and Reader, T.A. (1989) J. Neurosci. Res., 22, 338-45.
48. Porsolt, R.D., Bertin, A. and Jalfre, M. (1977) Arch. Int. Pharmacodyn. Ther., 229, 327-36.
49. Hascoet, M., Bourin, M. and Khimake, S. (1994) Prog. Neuropsychopharmacol. Biol. Psychiatry, 18, 381-96.
50. Nixon, M.K., Hascoet, M., Bourin, M. and Colombel, M.C. (1994) Psychopharmacology (Berl.), 115, 59-64.
51. Redrobe, J.P., Bourin, M., Colombel, M.C. and Baker, G.B. (1998) Psychopharmacology (Berl.), 138, 1-8.
52. Kitamura, Y., Araki, H., Suemaru, K. and Gomita, Y. (2002) Pharmacol. Biochem. Behav., 72, 397-402.
53. Gobert, A., Rivet, J.M., Cistarelli, L. and Millan, M.J. (1997) J. Neurochem., 68, 1159-63.
54. de Groote, L., Olivier, B. and Westerberg, H.G. (2002) Psychopharmacology (Berl.), 162, 419-24.
55. De Groote, L., Olivier, B. and Westenberg, H.G. (2002) Eur. J. Pharmacol., 439, 93-100.
56. Engel, G., Gothert, M., Hoyer, D., Schlicker, E. and Hillenbrand, K. (1986) Naunyn Schmiedebergs Arch. Pharmacol., 332, 1-7.
57. Hen, R. (1992) Trends Pharmacol. Sci., 13, 160-5.
58. Pineyro, G. and Blier, P. (1999) Pharmacol. Rev., 51, 533-91.
59. Adell, A., Celada, P. and Artigas, F. J Neurochem., 79, 172-82.
60. Gardier, A.M., Trillat, A.C., Malagie, I., David, D., Hascoet, M., Colombel, M.C., Jolliet, P., Jacquot, C., Hen, R. and Bourin, M. (2001) C. R. Acad. Sci. III, 324, 433-41.
61. Roberts, C., Watson, J., Price, G.W. and Middlemiss, D.N. (2001) CNS Drug. Rev., 7, 433-44.
62. Stenfors, C., Ahlgren, C., Yu, H., Weden, M., Larsson, L.G. and Ross, S.B. (2004) Psychopharmacology (Berl.), 172, 333-40.
63. Pineyro, G., Castanon, N., Hen, R. and Blier, P. (1995) Neuroreport, 7, 353-9.
64. Davidson, C. and Stamford, J.A. (1995) Br. J. Pharmacol., 114, 1107-9.
65. Hertel, P., Lindblom, N., Nomikos, G.G. and Svensson, T.H. (2001) Psychopharmacology (Berl.), 153, 307-14.
66. Pineyro, G., de Montigny, C. and Blier, P. (1995) Neuropsychopharmacology, 13, 249-60.
67. Starkey, S.J. and Skingle, M. (1994) Neuropharmacology, 33, 393-402.
68. Hopwood, S.E. and Stamford, J.A. (2001) Neuropharmacology, 40, 508-19.
69. Buhlen, M., Fink, K., Boing, C. and Gothert, M. (1996) Naunyn Schmiedebergs Arch. Pharmacol., 353, 281-9.
70. Hoyer, D. and Middlemiss, D.N. (1989) Trends Pharmacol. Sci., 10, 130-2.
71. Limberger, N., Deicher, R. and Starke, K. (1991) Naunyn Schmiedebergs Arch. Pharmacol., 343, 353-64.
72. Price, G.W., Burton, M.J., Collin, L.J., Duckworth, M., Gaster, L., Gothert, M., Jones, B.J., Roberts, C., Watson, J.M. and Middlemiss, D.N. (1997) Naunyn Schmiedebergs Arch. Pharmacol., 356, 312-20.
73. Schlicker, E., Fink, K., Molderings, G.J., Price, G.W., Duckworth, M., Gaster, L., Middlemiss, D.N., Zentner, J., Likungu, J. and Gothert, M. (1997) Naunyn Schmiedebergs Arch. Pharmacol., 356, 321-7.
74. Geyer, M.A. (1996) Behav. Brain Res., 73, 31-5.
75. Saudou, F., Amara, D.A., Dierich, A., LeMeur, M., Ramboz, S., Segu, L., Buhot, M.C. and Hen, R. (1994) Science, 265, 1875-8.
76. Dirks, A., Pattij, T., Bouwknecht, J.A., Westphal, T.T., Hijzen, T.H., Groenink, L., van der Gugten, J., Oosting, R.S., Hen, R., Geyer, M.A. and Olivier, B. (2001) Behav. Brain Res., 118, 169-78.
77. Boutrel, B., Franc, B., Hen, R., Hamon, M. and Adrien, J. (1999) J. Neurosci., 19, 3204-12.
78. Skingle, M., Beattie, D.T., Scopes, D.I., Starkey, S.J., Connor, H.E., Feniuk, W. and Tyers, M.B. (1996) Behav. Brain Res., 73, 157-61.
79. De Vry, J. and Schreiber, R. (2000) Neurosci. Biobehav. Rev., 24, 341-53.
80. Lucas, J.J., Yamamoto, A., Scearce-Levie, K., Saudou, F. and Hen, R. (1998) J. Neurosci., 18, 5537-44.
81. Tatarczynska, E., Klodzinska, A., Stachowicz, K. and Chojnacka-Wojcik, E. (2004) Behav. Pharmacol., 15, 523-34.
82. David, D.J., Bourin, M., Hascoet, M., Colombel, M.C., Baker, G.B. and Jolliet, P. (2001) Psychopharmacology (Berl.), 153, 443-9.
83. Redrobe, J.P., MacSweeney, C.P. and Bourin, M. (1996) Eur. J. Pharmacol., 318, 213-20.
84. Sarhan, H., Cloez-Tayarani, I., Massot, O., Fillion, M.P. and Fillion, G. (1999) Naunyn Schmiedebergs Arch. Pharmacol., 359, 40-7.
85. Bobker, D.H. and Williams, J.T. (1989) J. Pharmacol. Exp. Ther., 250, 37-43.
86. Maura, G. and Raiteri, M. (1986) Eur. J. Pharmacol., 129, 333-7.
87. Cassel, J.C., Jeltsch, H., Neufang, B., Lauth, D., Szabo, B. and Jackisch, R. (1995) Brain Res., 704, 153-66.
88. Feuerstein, T.J., Huring, H., van Velthoven, V., Lucking, C.H. and Landwehrmeyer, G.B. (1996) Neurosci. Lett., 209, 210-4.
89. Tatarczynska, E., Klodzinska, A., Stachowicz, K. and Chojnacka-Wojcik, E. (2004) Eur. J. Pharmacol., 487, 133-42.
90. Redrobe, J.P., Bourin, M., Colombel, M.C. and Baker, G.B. (1998) J. Psychopharmacol., 12, 348-55.
91. Moser, P.C. and Sanger, D.J. (1999) Eur. J. Pharmacol., 372, 127-34.
92. Tatarczynska, E., Klodzinska, A. and Chojnacka-Wojcik, E. (2002) Pol. J. Pharmacol., 54, 615-23.
93. Bourin, M., Hascoet, M., Colombel, M.C., Redrobe, J.P. and Baker, G.B. (1996) Eur. Neuropsychopharmacol., 6, 231-6.
94. Redrobe, J.P. and Bourin, M. (1997) Fundam. Clin. Pharmacol., 11, 381-6.
95. Szumlinski, K.K., Frys, K.A. and Kalivas, P.W. (2004) Neuropsychopharmacology 29, 1675-87.